AFIB patients complete first study using ACT technology

Advanced Cardiac Therapeutics’ (ACT) technology has been used to treat 12 patients suffering from Atrial Fibrillation (AFIB) in Prague, Czech Republic

The ACT first-in-man study was designed to evaluate the safety and effectiveness of its ACT system.  

The system combines a generator with a temperature-sensing, low flow catheter that incorporates multiple sensors into a diamond heat shunting, tip configuration. 

The technology controls lesion formation, reduces ablation times and reduces infused fluid volumes, according to ACT. 

The patients in the study were treated by the study's principal investigator, Vivek Reddy, director of cardiac arrhythmia services at Mount Sinai Hospital.

Reddy said: "What is truly extraordinary about the ACT technology is its ability to leverage temperature sensing to ablate efficiently, with ablation times that are reduced by over 50%.

“This technology provides a level of feedback to the operator that is greater than anything currently on the market and accordingly, the system has the potential to change the way electrophysiologists perform RF ablation for a host of arrhythmias, including AFIB."

ACT's CEO, Duke Rohlen, said: "The ACT system that was successfully used in humans last week validated its potential to completely redefine open-irrigated RF ablation technology."